Group 1: Future Industries and Financial Support - The Chinese government aims to establish a growth mechanism for future industries, focusing on sectors like biomanufacturing, quantum technology, embodied intelligence, and 6G by 2025 [1] - Banks are encouraged to innovate financial service models to support industrial transformation, as highlighted by the collaboration between Shanghai Pudong Development Bank and various companies in Shanghai, Nanjing, and Hangzhou [1] Group 2: Embodied Intelligence Development - "Embodied intelligence" was included in the government work report during the National People's Congress, indicating a strategic shift in AI development towards practical applications in industries such as robotics, healthcare, and services [2] - Shanghai Qingtong Intelligent Technology Co., Ltd. is a leading company in the global service robot industry, having deployed over 100,000 robots across more than 60 countries and 600 cities [4] Group 3: Robotics and Automation - Estun Automation Co., Ltd. is recognized as the highest domestic brand in industrial robots, with a comprehensive product line that meets various operational needs [5][7] - Estun has established a strategic partnership with Shanghai Pudong Development Bank, which has provided financial support during critical phases of the company's growth [7] Group 4: Financial Services for Emerging Companies - Zhejiang Hongshun Intelligent Technology Co., Ltd. focuses on commercial robots and has received 120 million yuan in loans from Shanghai Pudong Development Bank to support its development [10] - The biopharmaceutical sector is highlighted as a strategic and inclusive field, with companies like Jiachen Xihai Biotechnology Co., Ltd. leading in mRNA technology and receiving 60 million yuan in comprehensive credit from Shanghai Pudong Development Bank [11][13] Group 5: Comprehensive Financial Services Strategy - Shanghai Pudong Development Bank has established a "digital intelligence" strategy, focusing on technology finance, supply chain finance, inclusive finance, cross-border finance, and treasury finance as key areas of development [16] - The bank has served over 240,000 technology enterprises, including more than 70% of companies listed on the Science and Technology Innovation Board, with technology finance loans exceeding 1 trillion yuan [17]

Group 1 - The company, Heptagon Pharmaceuticals-B (02142), has entered into a placement agreement with a placement agent to issue a total of 45.022 million shares at a price of HKD 11.50 per share, conditional upon the agreement [1] - The placement price of HKD 11.50 represents a discount of approximately 9.45% compared to the closing price of HKD 12.70 on August 28, 2025 [1] - If all 45.022 million shares are fully subscribed, the net proceeds are expected to be approximately HKD 511.7 million [1] Group 2 - Approximately 50% of the net proceeds will be allocated for the research and development of innovative drug assets [1] - About 40% of the funds will be used to advance clinical trials for existing pipeline drug assets [1] - The remaining 10% will be designated for working capital and other general corporate purposes [1]